Joseph B Margolick1, Jay H Bream1, Tricia L Nilles1, Huifen Li2, Susan J Langan1, Shane Deng1, Ruibin Wang3, Nikolas Wada3, Sean X Leng2. 1. Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryl. 2. Division of Geriatric Medicine and Gerontology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryl. 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Abstract
Background: Both aging and treated human immunodeficiency virus (HIV)-infected populations exhibit low-level chronic immune activation of unknown etiology, which correlates with morbidity and mortality. Cytomegalovirus (CMV) infection is common in both populations, but its relation to immune activation is unknown. Methods: T cells from men who have sex with men (22 virologically suppressed HIV+, 20 HIV-) were stimulated with peptides spanning 19 CMV open reading frames, and intracellular cytokine responses were assessed. Soluble and cellular inflammatory markers were assessed by multiplex electrochemiluminescence and flow cytometry, respectively. Frailty was assessed by the Fried criteria. Results: All men had responses to CMV. Proportions of CMV-responsive T cells correlated strongly (r ≥ 0.6 or ≤ -0.6; P < .05) with immunologic markers, depending on donor HIV and frailty status. Markers significantly correlated in some groups after adjustment for multiple comparisons included interferon-γ, tumor necrosis factor-α, interleukin-6, and several chemokines in serum, and the proportion of activated T cells. The magnitude of the CD4 IL-2 response significantly predicted onset of frailty in HIV- nonfrail men, but not in HIV+ nonfrail men. Conclusions: T-cell responses to CMV may strongly influence chronic immune activation in HIV-uninfected and virologically suppressed HIV-infected men, and may predict frailty in HIV-uninfected men.
Background: Both aging and treated human immunodeficiency virus (HIV)-infected populations exhibit low-level chronic immune activation of unknown etiology, which correlates with morbidity and mortality. Cytomegalovirus (CMV) infection is common in both populations, but its relation to immune activation is unknown. Methods: T cells from men who have sex with men (22 virologically suppressed HIV+, 20 HIV-) were stimulated with peptides spanning 19 CMV open reading frames, and intracellular cytokine responses were assessed. Soluble and cellular inflammatory markers were assessed by multiplex electrochemiluminescence and flow cytometry, respectively. Frailty was assessed by the Fried criteria. Results: All men had responses to CMV. Proportions of CMV-responsive T cells correlated strongly (r ≥ 0.6 or ≤ -0.6; P < .05) with immunologic markers, depending on donorHIV and frailty status. Markers significantly correlated in some groups after adjustment for multiple comparisons included interferon-γ, tumor necrosis factor-α, interleukin-6, and several chemokines in serum, and the proportion of activated T cells. The magnitude of the CD4 IL-2 response significantly predicted onset of frailty in HIV- nonfrail men, but not in HIV+ nonfrail men. Conclusions: T-cell responses to CMV may strongly influence chronic immune activation in HIV-uninfected and virologically suppressed HIV-infectedmen, and may predict frailty in HIV-uninfectedmen.
Authors: Deborah L Regidor; Roger Detels; Elizabeth C Breen; Daniel P Widney; Lisa P Jacobson; Frank Palella; Charles R Rinaldo; Jay H Bream; Otoniel Martínez-Maza Journal: AIDS Date: 2011-01-28 Impact factor: 4.177
Authors: R Detels; L Jacobson; J Margolick; O Martinez-Maza; A Muñoz; J Phair; C Rinaldo; S Wolinsky Journal: Public Health Date: 2011-12-27 Impact factor: 2.427
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Sine Reker Hadrup; Jan Strindhall; Tania Køllgaard; Tina Seremet; Boo Johansson; Graham Pawelec; Per thor Straten; Anders Wikby Journal: J Immunol Date: 2006-02-15 Impact factor: 5.422
Authors: Allison E Aiello; Maryn Haan; Lynn Blythe; Kari Moore; Jeffrey M Gonzalez; William Jagust Journal: J Am Geriatr Soc Date: 2006-07 Impact factor: 5.562
Authors: Christine Kelly; Henry C Mwandumba; Robert S Heyderman; Kondwani Jambo; Raphael Kamng'ona; Mishek Chammudzi; Irene Sheha; Ingrid Peterson; Alicja Rapala; Jane Mallewa; A Sarah Walker; Nigel Klein; Saye Khoo Journal: J Infect Dis Date: 2019-05-24 Impact factor: 5.226
Authors: Janko Nikolich-Žugich; Luka Čicin-Šain; Donna Collins-McMillen; Sarah Jackson; Annette Oxenius; John Sinclair; Christopher Snyder; Mark Wills; Niels Lemmermann Journal: Geroscience Date: 2020-03-11 Impact factor: 7.713
Authors: Dana Gabuzda; Beth D Jamieson; Ronald G Collman; Michael M Lederman; Tricia H Burdo; Steven G Deeks; Dirk P Dittmer; Howard S Fox; Nicholas T Funderburg; Savita G Pahwa; Ivona Pandrea; Cara C Wilson; Peter W Hunt Journal: Pathog Immun Date: 2020-06-17
Authors: Sebastiaan O Verboeket; Ferdinand W Wit; Eveline Verheij; Rosan A van Zoest; Neeltje A Kootstra; Marc van der Valk; Jan M Prins; Maarten F Schim van der Loeff; Peter Reiss Journal: J Infect Dis Date: 2021-10-13 Impact factor: 5.226